Advanced Medical Solutions Reports Strong H1 2025 Results Driven by Acquisition

Advanced Medical Solutions Group plc (LSE:AMS) has posted robust interim results for the first half of 2025, with group revenue rising 63% to £110.8 million, fueled by the acquisition of Peters Surgical and ongoing organic growth. The integration of Peters Surgical and Syntacoll has improved manufacturing efficiency and expanded the company’s presence, particularly in cardiovascular markets. While gross margins saw a slight decline, adjusted EBITDA grew 42%, and profit before tax increased 49%. The Woundcare business has been successfully restructured into a cash-generative unit. AMS remains confident about sustaining growth, with plans for new product launches in the U.S. and further deleveraging by year-end.

The company’s outlook is supported by strong revenue momentum and a solid balance sheet, although shrinking profitability margins and elevated valuation temper expectations. Technical indicators point to a neutral trend, while the high P/E ratio suggests potential overvaluation, with dividend income offering limited yield.

About Advanced Medical Solutions Group plc

Advanced Medical Solutions Group plc (AMS) is an independent developer and manufacturer specializing in innovative tissue-healing technologies. Its portfolio includes surgical products such as tissue adhesives, sutures, haemostats, internal fixation devices, and sealants under brands like LiquiBand®, RESORBA®, and Peters Surgical. The company also offers wound care dressings, including silver alginates and foams, focusing on delivering quality patient outcomes and value for healthcare providers.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.